Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123
Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123
Repare Therapeutics和Debiopharm已在研究Lunersetib與Debio 0123聯合使用的1/1b期MYTHIC試驗中爲第一位患者服藥
Repare Therapeutics And Debiopharm Have Dosed The First Patient In Phase 1/1b MYTHIC Trial Investigating Lunresertib In Combination With Debio 0123
Repare Therapeutics和Debiopharm已在研究Lunersetib與Debio 0123聯合使用的1/1b期MYTHIC試驗中爲第一位患者服藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。